The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population
Abstract
Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for DNMT3A and TP53 increase only marginally, independent of cytosis or cytopenia. Nevertheless, large differences are observed between individuals carrying the same mutation, indicative of modulation by non-mutation-related factors. Clonal expansion is not dependent on classical cancer risk factors (e.g., smoking). Risk for incident myeloid malignancy diagnosis is highest for JAK2, spliceosome, or TP53 mutations and absent for DNMT3A, and it is mostly preceded by cytosis or cytopenia. The results provide important insight into high-risk evolutionary patterns to guide monitoring of "CHIP" and "CCUS."
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Comparison with previous studies19,57,58 showed the prevalence in our cohort was similar to a study of peripheral blood (PB) DNA from 3,359 individuals in the general population58 and to another hip replacement surgery cohort57”
From Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging (2024) · cites this paper as [58]
Citations
Cites
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
The origin and evolution of mutations in acute myeloid leukemia
Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Koboldt, D. C., Wartman, L. D., Lamprecht, T. L., Liu, F., Xia, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.023 · Cited by 1,575
Somatic mutation in cancer and normal cells
Martincorena, I., & Campbell, P. J. (2015) · Science · doi:10.1126/science.aab4082 · Cited by 1,396
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103283 · Cited by 1,222
Clonal hematopoiesis in human aging and disease
Jaiswal, S., & Ebert, B. L. (2019) · Science · doi:10.1126/science.aan4673 · Cited by 1,156
Tissue-specific mutation accumulation in human adult stem cells during life
Blokzijl, F., de Ligt, J., Jager, M., Sasselli, V., Roerink, S., Sasaki, N., Huch, M., Boymans, S., Kuijk, E., Prins, P., et al. (2016) · Nature · doi:10.1038/nature19768 · Cited by 935
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
Wong, T. N., Ramsingh, G., Young, A. L., Miller, C. A., Touma, W., Welch, J. S., Lamprecht, T. L., Shen, D., Hundal, J., Fulton, R. S., et al. (2015) · Nature · doi:10.1038/nature13968 · Cited by 892
Prediction of acute myeloid leukaemia risk in healthy individuals
Abelson, S., Collord, G., Ng, S. W. K., Weissbrod, O., Mendelson Cohen, N., Niemeyer, E., Barda, N., Zuzarte, P. C., Heisler, L., Sundaravadanam, Y., et al. (2018) · Nature · doi:10.1038/s41586-018-0317-6 · Cited by 850
Research works printed but not linked: 37
- Steensma, 2015, Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood, 126, 9, 10.1182/blood-2015-03-631747 · DOI · Paper page
- Bejar, 2017, CHIP, ICUS, CCUS and other four-letter words, Leukemia, 31, 1869, 10.1038/leu.2017.181 · DOI
- Malcovati, 2017, Clinical significance of somatic mutation in unexplained blood cytopenia, Blood, 129, 3371, 10.1182/blood-2017-01-763425 · DOI
- Kwok, 2015, MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance, Blood, 126, 2355, 10.1182/blood-2015-08-667063 · DOI
- Hansen, 2016, Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes, Am. J. Hematol., 91, 1234, 10.1002/ajh.24554 · DOI
- Khoury, 2022, The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms, Leukemia, 36, 1703, 10.1038/s41375-022-01613-1 · DOI · Paper page
- Arber, 2022, International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data, Blood, 140, 1200, 10.1182/blood.2022015850 · DOI · Paper page
- van Zeventer, 2021, Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years, Blood Adv., 5, 2115, 10.1182/bloodadvances.2020004062 · DOI
- Coombs, 2017, Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes, Cell Stem Cell, 21, 374, 10.1016/j.stem.2017.07.010 · DOI · Paper page
- Bolton, 2020, Cancer therapy shapes the fitness landscape of clonal hematopoiesis, Nat. Genet., 52, 1219, 10.1038/s41588-020-00710-0 · DOI · Paper page
- Dawoud, 2020, Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking, Leukemia, 34, 2660, 10.1038/s41375-020-0896-8 · DOI
- Jolly, 2018, Timing somatic events in the evolution of cancer, Genome Biol., 19, 95, 10.1186/s13059-018-1476-3 · DOI
- Robertson, 2022, Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects, Nat. Med., 28, 1439, 10.1038/s41591-022-01883-3 · DOI · Paper page
- van Zeventer, 2020, Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals, Blood, 135, 1161
- Kamphuis, 2023, Abnormal platelet counts and clonal hematopoiesis in the general population, Hemasphere, 7, e821, 10.1097/HS9.0000000000000821 · DOI
- Kar, 2022, Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis, Nat. Genet., 54, 1155, 10.1038/s41588-022-01121-z · DOI · Paper page
- Niroula, 2021, Distinction of lymphoid and myeloid clonal hematopoiesis, Nat. Med., 27, 1921, 10.1038/s41591-021-01521-4 · DOI
- Zink, 2017, Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly, Blood, 130, 742, 10.1182/blood-2017-02-769869 · DOI · Paper page
- Jongen-Lavrencic, 2018, Molecular minimal residual disease in acute myeloid leukemia, N. Engl. J. Med., 378, 1189, 10.1056/NEJMoa1716863 · DOI
- Graubert, 2011, Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes, Nat. Genet., 44, 53, 10.1038/ng.1031 · DOI
- Papaemmanuil, 2013, Clinical and biological implications of driver mutations in myelodysplastic syndromes, Blood, 122, 3616, 10.1182/blood-2013-08-518886 · DOI · Paper page
- van Zeventer, 2022, Monocytosis and its association with clonal hematopoiesis in community-dwelling individuals, Blood Adv., 6, 4174, 10.1182/bloodadvances.2021006755 · DOI
- Gallì, 2021, Relationship between clone metrics and clinical outcome in clonal cytopenia, Blood, 138, 965, 10.1182/blood.2021011323 · DOI
- Saiki, 2021, Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis, Nat. Med., 27, 1239, 10.1038/s41591-021-01411-9 · DOI
- Cordua, 2019, Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population, Blood, 134, 469, 10.1182/blood.2019001113 · DOI
- Young, 2013, Current concepts in the pathophysiology and treatment of aplastic anemia, Hematology. Am. Soc. Hematol. Educ. Program, 2013, 76, 10.1182/asheducation-2013.1.76 · DOI
- Ogawa, 2016, Clonal hematopoiesis in acquired aplastic anemia, Blood, 128, 337, 10.1182/blood-2016-01-636381 · DOI
- Kristinsson, 2011, Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes, J. Clin. Oncol., 29, 2897, 10.1200/JCO.2011.34.8540 · DOI · Paper page
- Fleischman, 2011, TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms, Blood, 118, 6392, 10.1182/blood-2011-04-348144 · DOI
- Silver, 2021, Germline risk of clonal haematopoiesis, Nat. Rev. Genet., 22, 603, 10.1038/s41576-021-00356-6 · DOI
- Gao, 2021, Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis, Nat. Commun., 12, 338, 10.1038/s41467-020-20565-7 · DOI
- Cargo, 2015, Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression, Blood, 126, 2362, 10.1182/blood-2015-08-663237 · DOI
- Scholtens, 2015, Cohort Profile: LifeLines, a three-generation cohort study and biobank, Int. J. Epidemiol., 44, 1172, 10.1093/ije/dyu229 · DOI · Paper page
- Klijs, 2015, Representativeness of the LifeLines cohort study, PLoS One, 10, e0137203, 10.1371/journal.pone.0137203 · DOI
- Slagter, 2013, Associations between smoking, components of metabolic syndrome and lipoprotein particle size, BMC Med., 11, 195, 10.1186/1741-7015-11-195 · DOI
- Siebelink, 2011, Self-reported energy intake by FFQ compared with actual energy intake to maintain body weight in 516 adults, Br. J. Nutr., 106, 274, 10.1017/S0007114511000067 · DOI
- Schouten, 1993, Completeness of cancer registration in Limburg, The Netherlands, Int. J. Epidemiol., 22, 369, 10.1093/ije/22.3.369 · DOI
Cited by
Jakobsen, N. A., Turkalj, S., Zeng, A. G. X., Stoilova, B., Metzner, M., Rahmig, S., Nagree, M. S., Shah, S., Moore, R., Usukhbayar, B., et al. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.05.010 · Cited by 130
Metadata
- Authors
- van Zeventer, I. A., de Graaf, A. O., Salzbrunn, J. B., Nolte, I. M., Kamphuis, P., Dinmohamed, A., van der Reijden, B. A., Schuringa, J. J., Jansen, J. H., & Huls, G.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2023-06
- Volume
- 41
- Issue
- 6
- Pages
- 1017-1031.e4
- ISSN
- 1535-6108
- Cited by
- 91
- References
- 23
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 377 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- European Union
- Rijksuniversiteit Groningen
- Horizon 2020 Framework Programme
- Ministerie van Volksgezondheid, Welzijn en Sport
- Ministerie van Economische Zaken
- Horizon 2020 (634789)
- Stanford Genome Technology Center
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population. https://app.cochat.ai/papers/10.1016/j.ccell.2023.04.006
- The paper
- van Zeventer, I. A., de Graaf, A. O., Salzbrunn, J. B., Nolte, I. M., Kamphuis, P., Dinmohamed, A., van der Reijden, B. A., Schuringa, J. J., Jansen, J. H., & Huls, G. (2023). Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population. Cancer Cell. https://doi.org/10.1016/j.ccell.2023.04.006